Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles
ConclusionRabeprazole 5 mg bid provided no therapeutic advantage for acid inhibition compared with rabeprazole 10 mg qd, regardless of CYP2C19 genotype status.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Aspirin | Drugs & Pharmacology | Gastroenterology | Insurance | Japan Health | Proton Pump Inhibitors PPIs